Mounjaro Discounts: What You May Actually Pay in 2026

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

“Mounjaro discount” searches are really about one thing: how far the real price can drop from the number on the shelf. The answer depends on insurance, the FDA indication on the prescription, savings-card eligibility, pharmacy pricing, and whether a compounded formulation is available. This article walks through each lever in turn and lays out what typical out-of-pocket scenarios actually look like as of April 2026.

List price is only the starting line

Mounjaro’s list price is approximately $1,069 per month at U.S. list as of April 2026 (Eli Lilly published pricing). That figure comes before insurance, rebates, savings cards, and pharmacy negotiation. Every discount lever discussed here works against that starting number rather than replacing it.

Coverage, prior authorization, and Medicare

Commercial coverage hinges on the FDA indication written and the plan’s formulary and prior-authorization rules. Many commercial plans cover GLP-1 receptor agonists for type 2 diabetes; weight-management coverage varies more widely, is often gated by BMI-based prior authorization, and some plans exclude it entirely. Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, though cardiovascular-indication coverage exists for some products.

Discount levers that actually move the number

Eli Lilly publishes a manufacturer savings-card program that can substantially reduce cost for eligible commercially-insured patients, though it typically excludes Medicare, Medicaid, TRICARE, and other government-funded insurance, and it carries monthly and annual caps. Independent platforms like GoodRx and SingleCare add cash-price coupons that vary by pharmacy. Verify terms at the time of fill.

The 2024–2025 compounding shift

During the FDA-declared shortages, 503A compounding pharmacies legally produced compounded semaglutide and tirzepatide. The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, which narrowed the compounding window without eliminating all legitimate activity. Compounded products remain available through licensed pathways where clinically justified; they are not identical to the brand and are priced separately.

What the out-of-pocket scenarios look like

With commercial insurance that covers the indication and the savings card applied, eligible patients may pay as little as $25 per month depending on plan terms and caps. With commercial insurance that does not cover the indication, cash-pay lands closer to list price minus any coupon. Without insurance, cash-pay approaches list; compounded alternatives through the PlexusDx Weight Management Protocols follow a separate pricing structure published on each product page.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral.

The upstream layer no discount addresses is genetic. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, GLP1R, and MC4R variants that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that profile alongside the protocol is the test before you invest approach — turning guesswork into an informed provider conversation.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology underneath every decision. Take the Precision Peptide Genetic Test, or explore the protocol directly.

Frequently Asked Questions

How low can the real price of Mounjaro go?

It varies widely. With commercial insurance covering the indication and the savings card applied, eligible patients may pay as little as $25 per month depending on plan terms and caps. Without coverage, cash-pay approaches the roughly $1,069 list price minus any coupon, though compounded options are priced separately.

Does Medicare cover Mounjaro?

Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, and manufacturer savings cards typically exclude government-insurance patients. Coverage for other indications, including some cardiovascular indications, can exist. Check your specific plan and the indication written on the prescription for a definitive answer.

Are compounded versions a cheaper route?

Compounded semaglutide and tirzepatide from licensed 503A pharmacies are priced separately from the brand and have historically fallen below list price. They are not identical to FDA-approved products and are not generics. Availability narrowed after the shortages resolved in late 2024 and early 2025 but did not disappear.

Does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

It does not predict response to Mounjaro or which discount is best. It analyzes pathway-level variants in FTO, and MC4R that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across every GLP-1 compound regardless of how you reduce the price.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education